Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences (Nasdaq: TLSA) announced on June 10, 2022, that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 50,000 common shares at $0.88 each. This acquisition increased Cerrone's stake from 37.60% to 37.64%. Tiziana specializes in developing innovative immunotherapy delivery methods, focusing on alternative routes such as nasal, oral, and inhalation. Their leading candidates include intranasal foralumab and milciclib, both of which have shown favorable safety profiles in clinical studies.

Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second patient in a secondary progressive multiple sclerosis (SPMS) trial. The patient showed improvements in PET analysis and neurologic exams after three months of treatment with intranasal foralumab. Following these findings, the FDA approved the enrollment of eight additional patients in the trial. Tiziana aims to escalate dosing to potentially enhance clinical benefits. The company anticipates enrolling the third patient by July 2022 and expects to release data on all ten patients in 2023.

Tiziana Life Sciences (TLSA) announced positive clinical outcomes from its ongoing study on Foralumab for patients with Secondary Progressive Multiple Sclerosis (SPMS) during a recent interview. Conducted at Brigham and Women’s Hospital, the trial highlights the potential of Foralumab, the only fully human anti-CD3 mAb, in managing autoimmune diseases. The treatment has shown favorable safety profiles and effective immune response modulation. Tiziana focuses on innovative drug delivery technologies, aiming to improve patient outcomes by offering alternative routes for immunotherapy.

Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second patient with secondary progressive multiple sclerosis (SPMS) on June 8, 2022. The patient demonstrated significant clinical improvements, including a 10-30% reduction in microglial activation after three months of treatment with intranasal foralumab. Following the success of the first two patients, the FDA has approved the enrollment of eight more patients under the Expanded Access Program. The company aims to investigate higher dosing levels and expects to enroll a third patient in July 2022.

Tiziana Life Sciences (Nasdaq: TLSA) has announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, acquired 18,000 common shares at $0.80 each. This purchase increased Cerrone’s beneficial ownership from 37.58% to 37.60% of the company. Tiziana is focused on developing innovative immunotherapies using alternative drug delivery methods, including intranasal and inhalation approaches, with its lead candidates showing favorable safety profiles and clinical responses.

Tiziana Life Sciences (Nasdaq: TLSA) announced promising clinical results for its intranasal therapy with foralumab in treating Secondary Progressive Multiple Sclerosis (SPMS). Positive outcomes were observed in two patients, demonstrating improvements in PET imaging and neurologic exams after three months of treatment. The FDA has authorized enrollment of an additional eight SPMS patients in the expanded access program. Both patients continue treatment, with the potential for dosage escalation to enhance clinical benefits.

Tiziana Life Sciences (NASDAQ: TLSA) announced that CEO Kunwar Shailubhai will present at the BIO Annual Convention in San Diego from June 13-16, 2022. His focus will be on recent clinical updates for foralumab, an anti-CD3 monoclonal antibody, specifically regarding nasal administration for secondary progressive multiple sclerosis. Additionally, he will discuss the Phase 1b trial for oral capsules of foralumab aimed at treating Crohn’s Disease. Tiziana's management will also conduct one-on-one meetings at the event.

Tiziana Life Sciences (TLSA) announced Dr. Tanuja Chitnis will present clinical data on foralumab, an intranasal anti-CD3 monoclonal antibody, at the CMSC 2022 Annual Meeting from June 1-4. This presentation will focus on a patient with secondary progressive multiple sclerosis treated for six months. The data highlights the potential of foralumab to reduce microglial activation and blood inflammatory markers. The session is scheduled for June 2, 2022, at 5 PM EDT. Foralumab, a unique human anti-CD3 mAb, shows promise in treating autoimmune diseases.

Tiziana Life Sciences (Nasdaq: TLSA) announced the filing of its Annual Report on Form 20-F for the year ended December 31, 2021, on May 23, 2022. Following this filing, the company confirmed it has regained compliance with Nasdaq Listing Rules. Tiziana is focused on developing innovative immunotherapy delivery methods, including intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody, and milciclib, a pan-CDK inhibitor. The company’s alternative drug delivery technologies aim to enhance efficacy, safety, and tolerability.